Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Endocrinology

Articles with lock require a GLG News subscription
Posted October 23, 2007
Pfizer Abandons Exubera, Posts 77% Earnings Decline
Analysis of: Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Author: GLG Member Program Contributor
There remains a very important message to be learned from from Pfizer closing  the doors on Exubera: physicians and other prescribers are not yet  ready to embrace inhaled insulin.  Despite the clinical results that  Big Pharma may present, many health care professionals are incredibly...
Tim Gallagher Posted October 22, 2007
Exit Exubera
Analysis of: Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Author: Tim Gallagher, Executive Vice President of Pharmacy Operations Astrup Drug, Inc.
Pfizer failed miserably in its attempt to provide diabetic patients with an easy-to-use inhaled insulin as an alternative to injectable insulin. A product they projected would generate sales of $2 billion a year recorded a disappointing $12 million in sales this year. CEO Kindler said he decided to...
Posted October 22, 2007
Pfizer Abandons Exubera, Posts 77% Earnings Decline
Analysis of: Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Author: GLG Member Program Contributor
Pfizer seemed to make several disastrous assumptions in bringing Exubera to the market.  First, that patients would be willing to sacrifice simplicity to avoid a needle.  Second, that insurers would be willing to pay for it.  Finally, perhaps most importantly, that doctors had...
Posted October 22, 2007
Pfizer Abandons Exubera, Posts 77% Earnings Decline
Analysis of: Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Author: GLG Member Program Contributor
As posted previously, the problem with Exubera was the cumbersome device and the inability to control exact doses. The respiratory precautions with "need" for spirometry made it much less appealing.  Inhaled insulins still have a place if these issues can be overcome.
Posted October 22, 2007
Amgen Defends Its Turf as Competition Looms for Anemia Drug
Analysis of: Amgen Defends Its Turf as Competition Looms for Anemia Drug | www.nytimes.com
Author: GLG Member Program Contributor
While the competitive nature of pharmaceutical industry is well known, this article provides fascinating insights into the dirty tricks department.
Posted October 22, 2007
Pfizer Abandons Exubera, Posts 77% Earnings Decline
Analysis of: Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Author: GLG Member Program Contributor
Traditional analysis is correct regarding Pfizer's decision to withdraw inhaled insulin (Exubera) from the market. The fallout from the cascade of bad decisions and market misunderstanding points to the need to underscore one important point, value. Election year politics equates value to regulation....
Posted October 22, 2007
Pfizer Abandons Exubera, Posts 77% Earnings Decline
Analysis of: Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Author: GLG Member Program Contributor
Due to poor sales, Pfizer has decided to pull the plug on Exubera (inhaled insulin).  This will have a signficant impact on other companies who are developing other inhaled insulin products.
Posted October 19, 2007
Pfizer Abandons Exubera, Posts 77% Earnings Decline
Analysis of: Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Author: GLG Member Program Contributor
Ask any patient with diabetes what they want for a therapeutic option and they'll tell you non-injectable insulin.  They understand that all the other medications are a poor substitution for the replacement of pancreatic insulin and they are tired of taking multiple pills each day. So why did...
Posted October 19, 2007
A can of tennis balls?
Analysis of: Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Author: David Zimmerman, President/Owner Doctors of Pharmacy, Inc.
Exubera is a great product. However, the delivery system was difficult to use and educate the patients how to use. Hopefully, the next generation of the product will be in a smaller more user friendly cannister.
Posted October 18, 2007
FDA Warns of Pancreatitis Risk Associated With Diabetes Drug
Analysis of: FDA Warns of Pancreatitis Risk Associated With Diabetes Drug | online.wsj.com
Author: GLG Member Program Contributor
Though being an excellent drug, the nausea side effect has precluded its use in a fair number of patients. The concern regarding potential pancreatitis will make patients even more leary of it.
Previous Page : 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Next141 to 150 of 364

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses

Azilect
September 2, 2008

Byetta Saves Lives
September 2, 2008

The Devil Is in the Details
September 1, 2008

Dangers of Methadone Usage
August 28, 2008

Healthways A Market Downturn and Results
August 26, 2008

 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-09-05T01:45:16.907